poisar

Stocks · News reference

JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425

Benzinga Newsdesk

JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HCA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Can Operational Resiliency Protect HCA's Long-Term Profitability?

    HCA Healthcare is leveraging its multi-year resiliency program focused on digital transformation and shared services to control unit costs and maintain profitability despite facing a $1.0-$1.2 billion headwind from health insurance exchange disenrollment in 2026. The company achieved flat year-over-year cost per admission in Q2 and targets 4-6% long-term adjusted EBITDA growth. Peers Tenet Healthcare and Universal Health Services are similarly pursuing operational efficiency initiatives.

    HCATHCUHS
  3. Bragar Eagel & Squire, P.C.

    HCA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating HCA Healthcare, Inc. on Behalf of HCA Stockholders and Encourages Investors to Contact the Firm

    Law firm Bragar Eagel & Squire is investigating HCA Healthcare for potential federal securities law violations following the company's July 14, 2026 announcement of sharply lowered full-year profit guidance due to unfavorable payer mix changes impacting revenue by approximately $400 million. HCA's stock fell 6.95% ($27.14 per share) to $363.60 on the news. The firm is seeking stockholders who suffered losses to participate in the action.

    HCA